COMMUNIQUÉS West-GlobeNewswire

Leios Therapeutics Announces Positive End-of-Phase 2 Meeting with FDA for 10XB-101 for Moderate-to-Severe Submental Fat Fullness
14/09/2026
Alignment Reached on Key Elements of the Phase 3 Program to Support a 505(b)(2) NDA Submission 10XB-101 Now has Clear Regulatory Path Forward LA JOLLA, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Leios Therapeutics (“ [...]
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
14/09/2026
Clinical study to evaluate NS002, the Company's investigational intranasal epinephrine powder, as a needle-free alternative to EpiPen® for patients experiencing anaphylaxis and will compare self-administration to [...]
Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models
14/09/2026
Preclinical Findings Support Parallel Development Pathway in Canine Osteosarcoma as TNBC Program Advances Toward Site Initiation MIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a [...]
Baird Medical Highlights Participation at CIRSE 2026 and Showcases Microwave Ablation Technology
14/09/2026
Company Engaged with Interventional Radiology Community at Leading Global Congress in Copenhagen COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (“Baird Medical” or the “ [...]
Revelyx Bio Reports Positive Topline Phase 2 Results for YY003, a Recombinant, Ready-to-Use Liquid Botulinum Toxin Type A, in Moderate-to-Severe Glabellar Lines
14/09/2026
Study met its primary endpoints: 80.8% of participants receiving 40 U achieved the composite response at Week 4 versus 0% with vehicle (p<0.001); YY003 was well tolerated, with no treatment-related serious adverse [...]
Alveus Therapeutics Initiates Phase 2 PRESERVE Trial to Evaluate ALV-100 for Chronic Weight Management
14/09/2026
BOSTON and COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Alveus Therapeutics Inc. (“Alveus”), a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, [...]
Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
14/09/2026
PARSIPPANY, N.J. and TEL AVIV, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a global biopharmaceutical company, today announced that its ordinary shares will [...]
Santa Ana Bio Announces First Subjects Dosed in Phase 1 Study of SAB01 to Treat Autoimmune Inflammatory Diseases
14/09/2026
First-in-class bispecific antibody designed for mast cell elimination without the safety issues associated with current KIT therapeutics Phase 1 single ascending dose study to evaluate the safety, pharmacokinetics, and [...]
Nord Fascia Launches Personalized Fascia Release and Mobility App
14/09/2026
Nord Fascia App Turns a Short Quiz Into a Daily Fascia Release and Stretching Routine NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Nord Fascia has launched a personalized wellness app built around fascia release, [...]
Tris Pharma Introduces New 30-Count Bottle Size for QuilliChew ER® (methylphenidate HCl) Extended-Release Chewable Tablets for Attention Deficit Hyperactivity Disorder (ADHD)
14/09/2026
A new, smaller 30-count bottle of the once-daily chewable methylphenidate offers pharmacists easier stocking and patients a 30-day supply at common dosing levels, available now as families navigate the back-to-school [...]
GATC Health Joins Critical Path Institute’s New Approach Methodologies Developer Coalition to Advance AI-Enabled Regulatory Science
14/09/2026
GATC to contribute AI-native, in silico drug discovery and predictive modeling expertise and insights to collaborative effort advancing the validation, qualification and adoption of human-relevant drug development tools [...]
Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement
14/09/2026
Under the terms of the Amendment, all disputed issues are resolved SAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l [...]
Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex’s Highly Qualified Director Nominees
14/09/2026
ISS Recognizes There is No Case for Change Anavex Urges Stockholders to Follow ISS’ Recommendation and Vote “FOR” ALL Six Director Nominees on the WHITE Proxy Card Today NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- [...]
Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
14/09/2026
Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition CINCINNATI, [...]
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
14/09/2026
RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden Additional Data and Updates on Regulatory Discussions Anticipated in 4Q [...]
Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings
14/09/2026
Presentations examine where Annamycin concentrates in the body, how it targets topoisomerase II, and its antitumor activity in pancreatic cancer HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. ( [...]
Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
14/09/2026
- Enrollment of 239 Patients Meets Upper End of Planned Enrollment Target Range - - Topline Data Expected in November 2026 - ATLANTA, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“ [...]
Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil
14/09/2026
Published Phase 1 data in Sexual Medicine strengthen the scientific foundation for Daré Bioscience’s proprietary topical Sildenafil Cream, 3.6% At the 71 mg topical dose, mean maximum plasma concentration of sildenafil [...]
Unlocking the Growth - Invitation to BioPorto’s investor meeting on Oct 7
14/09/2026
September 14, 2026 News release Unlocking the Growth - Invitation to BioPorto’s investor meeting on October 7 As BioPorto continues to advance its commercial strategy and capitalize on emerging clinical opportunities, [...]

Pages